Live Breaking News & Updates on Sahm Nasseri|Page 3
Stay updated with breaking news from Sahm nasseri. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Share this article Share this article NEW YORK and PERTH, Australia, March 17, 2021 /PRNewswire/ PYC Therapeutics (ASX: PYC), a biotechnology company developing a new generation of precision RNA therapeutics to change the lives of patients with inherited diseases, today announced the appointment of Michael Rosenblatt, MD, to its Board of Directors. Dr. Rosenblatt is a Senior Partner at Flagship Pioneering, a leading-edge innovation organization that conceives, creates and develops first-in-category life science companies, and the former Chief Medical Officer of Merck, one of the world s leading global biopharmaceutical companies. Dr. Rosenblatt brings over four decades of visionary leadership experience across biopharmaceutical companies and academic institutions, and as a practicing physician. In his current role at Flagship, he has helped launch several renowned biotechnology companies in the Flagship ecosystem, including providing counsel on clinical development ....
Share this article Share this article NEW YORK and PERTH, Australia, March 2, 2021 /PRNewswire/ PYC Therapeutics (ASX: PYC), a biotechnology company developing a new generation of precision RNA therapeutics to change the lives of patients with inherited diseases, today announced that the Company s lead investigational drug, VP-001, for the treatment of RP11 has restored function of the Retinal Pigment Epithelium, the target cells for the therapy, in patient-derived models of the disease. Figure 1. Structure of the retina and changes in RP-11 patients Image created using Biorender.com Figure 2. VP-001 treatment improves barrier function in penetrant patient iPSC-RPE Barrier function is assessed by trans-epithelial electrical resistance, T.E.E.R. (measured in Ω.cm2), with increasing Ω.cm2 representing increasing barrier function. Statistical significance calculated as one-way ANOVA = p ≤ 0.05 in cells from a single patient across two technical replicate ....
Share this article Share this article PERTH, Australia and NEW YORK, Feb. 23, 2021 /PRNewswire/ PYC Therapeutics (ASX: PYC), a biotechnology company developing a new generation of precision RNA therapeutics to change the lives of patients with inherited diseases, today announced the appointment of Glenn Noronha, PhD, as Chief Development Officer. Dr. Noronha will oversee the Company s translational clinical development, regulatory, manufacturing and preclinical development activities as it advances its pipeline of multiple drug candidates which is initially focused on inherited ocular diseases. Dr. Noronha brings to PYC over 20 years of progressive leadership and research experience across both small and large biotechnology and pharmaceutical companies, with deep expertise in development of ophthalmology drug candidates, through his positions at BridgeBio Pharma, Clearside Biomedical and Alcon, formerly the ophthalmology subsidiary of Novartis. He has a proven tra ....
Share this article Share this article PERTH, Australia and NEW YORK, Feb. 22, 2021 /PRNewswire/ PYC Therapeutics (ASX: PYC), a biotechnology company developing a new generation of precision RNA therapeutics to change the lives of patients with inherited diseases, today announced updates to its programs and outlined its 2021-2022 corporate objectives. PYC is initially targeting inherited ocular diseases, for which it has three preclinical candidates in development. This year we are focused on transforming PYC Therapeutics into a U.S.-based, clinical-stage biotechnology company, including making significant advances in moving our three preclinical inherited ocular disease programs toward the clinic and leveraging our RNA platform to create new development candidates in both ocular and neurodegenerative diseases, said Sahm Nasseri, U.S. Chief Executive Officer of PYC Therapeutics. We have previously highlighted the importance of building out PYC in the U.S. and I am ....